Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.

BACKGROUND: Although the Newcastle disease virus (NDV) inactivated vaccines and attenuated live vaccines have been used to prevent and control Newcastle disease (ND) for years, there are some disadvantages. Recently, newly developed DNA vaccines have the potential to overcome these disadvantages. Th...

Full description

Bibliographic Details
Main Authors: Kai Zhao, Wei Li, Tingting Huang, Xiaomei Luo, Gang Chen, Yang Zhang, Chen Guo, Chunxiao Dai, Zheng Jin, Yan Zhao, Hongyu Cui, Yunfeng Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3873271?pdf=render
id doaj-70687a1689544b03b7b28e6e18b5d815
record_format Article
spelling doaj-70687a1689544b03b7b28e6e18b5d8152020-11-25T01:18:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8264810.1371/journal.pone.0082648Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.Kai ZhaoWei LiTingting HuangXiaomei LuoGang ChenYang ZhangChen GuoChunxiao DaiZheng JinYan ZhaoHongyu CuiYunfeng WangBACKGROUND: Although the Newcastle disease virus (NDV) inactivated vaccines and attenuated live vaccines have been used to prevent and control Newcastle disease (ND) for years, there are some disadvantages. Recently, newly developed DNA vaccines have the potential to overcome these disadvantages. The low delivery efficiency, however, hindered the application of DNA vaccines for ND in practice. METHODOLOGY/PRINCIPAL FINDINGS: The eukaryotic expression plasmid pVAX1-F (o) DNA that expressed the F gene of NDV encapsulated in PLGA nanoparticles (pFNDV-PLGA-NPs) were prepared by a double emulsion-solvent evaporation method and optimal preparation conditions of the pFNDV-PLGA-NPs were determined. Under the optimal conditions, the pFNDV-PLGA-NPs were produced in good morphology and had high stability with a mean diameter of 433.5 ± 7.5 nm, with encapsulation efficiency of 91.8 ± 0.3% and a Zeta potential of +2.7 mV. Release assay in vitro showed that the fusion gene plasmid DNA could be sustainably released from the pFNDV-PLGA-NPs up to 93.14% of the total amount. Cell transfection test indicated that the vaccine expressed and maintained its bioactivity. Immunization results showed that better immune responses of SPF chickens immunized with the pFNDV-PLGA-NPs were induced compared to the chickens immunized with the DNA vaccine alone. In addition, the safety of mucosal immunity delivery system of the pFNDV-PLGA-NPs was also tested in an in vitro cytotoxicity assay. CONCLUSIONS/SIGNIFICANCE: The pFNDV-PLGA-NPs could induce stronger cellular, humoral, and mucosal immune responses and reached the sustained release effect. These results laid a foundation for further development of vaccines and drugs in PLGA nanoparticles.http://europepmc.org/articles/PMC3873271?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kai Zhao
Wei Li
Tingting Huang
Xiaomei Luo
Gang Chen
Yang Zhang
Chen Guo
Chunxiao Dai
Zheng Jin
Yan Zhao
Hongyu Cui
Yunfeng Wang
spellingShingle Kai Zhao
Wei Li
Tingting Huang
Xiaomei Luo
Gang Chen
Yang Zhang
Chen Guo
Chunxiao Dai
Zheng Jin
Yan Zhao
Hongyu Cui
Yunfeng Wang
Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
PLoS ONE
author_facet Kai Zhao
Wei Li
Tingting Huang
Xiaomei Luo
Gang Chen
Yang Zhang
Chen Guo
Chunxiao Dai
Zheng Jin
Yan Zhao
Hongyu Cui
Yunfeng Wang
author_sort Kai Zhao
title Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
title_short Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
title_full Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
title_fullStr Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
title_full_unstemmed Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.
title_sort preparation and efficacy of newcastle disease virus dna vaccine encapsulated in plga nanoparticles.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description BACKGROUND: Although the Newcastle disease virus (NDV) inactivated vaccines and attenuated live vaccines have been used to prevent and control Newcastle disease (ND) for years, there are some disadvantages. Recently, newly developed DNA vaccines have the potential to overcome these disadvantages. The low delivery efficiency, however, hindered the application of DNA vaccines for ND in practice. METHODOLOGY/PRINCIPAL FINDINGS: The eukaryotic expression plasmid pVAX1-F (o) DNA that expressed the F gene of NDV encapsulated in PLGA nanoparticles (pFNDV-PLGA-NPs) were prepared by a double emulsion-solvent evaporation method and optimal preparation conditions of the pFNDV-PLGA-NPs were determined. Under the optimal conditions, the pFNDV-PLGA-NPs were produced in good morphology and had high stability with a mean diameter of 433.5 ± 7.5 nm, with encapsulation efficiency of 91.8 ± 0.3% and a Zeta potential of +2.7 mV. Release assay in vitro showed that the fusion gene plasmid DNA could be sustainably released from the pFNDV-PLGA-NPs up to 93.14% of the total amount. Cell transfection test indicated that the vaccine expressed and maintained its bioactivity. Immunization results showed that better immune responses of SPF chickens immunized with the pFNDV-PLGA-NPs were induced compared to the chickens immunized with the DNA vaccine alone. In addition, the safety of mucosal immunity delivery system of the pFNDV-PLGA-NPs was also tested in an in vitro cytotoxicity assay. CONCLUSIONS/SIGNIFICANCE: The pFNDV-PLGA-NPs could induce stronger cellular, humoral, and mucosal immune responses and reached the sustained release effect. These results laid a foundation for further development of vaccines and drugs in PLGA nanoparticles.
url http://europepmc.org/articles/PMC3873271?pdf=render
work_keys_str_mv AT kaizhao preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT weili preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT tingtinghuang preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT xiaomeiluo preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT gangchen preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT yangzhang preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT chenguo preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT chunxiaodai preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT zhengjin preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT yanzhao preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT hongyucui preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
AT yunfengwang preparationandefficacyofnewcastlediseasevirusdnavaccineencapsulatedinplgananoparticles
_version_ 1725140182215163904